Gouvernance PTC Therapeutics, Inc. Berne S.E.

P91

US69366J2006

Produits pharmaceutiques

Temps Différé Berne S.E. Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^CHF	-.--%		-.--%	-

07/07	PTC THERAPEUTICS, INC. : RBC Capital Markets maintient sa recommandation neutre	ZM
16/06	PTC Therapeutics fixe les conditions d'une émission obligataire de 500 millions de dollars	MT

Comité Exécutif: PTC Therapeutics, Inc.

Dirigeant

Fonctions occupéesDepuis

Matthew Klein

54 ans

Chief Executive Officer	22/03/2023
President	22/03/2023

Lee Golden

58 ans

Chief Tech/Sci/R&D Officer

01/01/2022

Linda Montella-Carter

Chief Tech/Sci/R&D Officer

01/10/2017

Gabriel Holdsman

General Counsel	01/04/2018
Corporate Secretary	01/04/2018

Pierre Gravier

41 ans

Director of Finance/CFO

13/07/2023

Hege Sollie-Zetlmayer

Human Resources Officer

01/01/2018

Ellen Cavaleri

Investor Relations Contact

01/11/2024

Christine Utter

48 ans

Comptroller/Controller/Auditor

Murad Husain

General Counsel

29/01/2014

Neil Almstead

59 ans

Chief Tech/Sci/R&D Officer

01/12/2015

Mark Boulding

65 ans

General Counsel

01/01/2002

John Baird

Human Resources Officer

01/03/2023

Composition du Conseil d'Administration: PTC Therapeutics, Inc.

Administrateur

ComitésDepuis

Michael Schmertzler

74 ans

Compensation Committee
Governance Committee	21/05/2013
Nominating Committee	21/05/2013

David Southwell

65 ans

Audit Committee
Compensation Committee	21/05/2013
Compensation Committee Chair	01/01/2018
Governance Committee Chair	01/01/2018
Nominating Committee Chair	01/01/2018

Jerome Zeldis

76 ans

Compensation Committee	13/05/2015
Governance Committee Chair	01/04/2020
Nominating Committee Chair	01/04/2020
Governance Committee
Nominating Committee

Stephanie Okey

66 ans

Governance Committee Chair	18/12/2018
Nominating Committee Chair	18/12/2018
Governance Committee	15/07/2019
Nominating Committee	15/07/2019
Compensation Committee Chair

Emma Reeve

65 ans

Compensation Committee	18/12/2018
Audit Committee Chair	08/09/2021

Mary Smith

63 ans

Audit Committee
Compensation Committee

Jessica Chutter

65 ans

Audit Committee

08/06/2026

Glenn Steele

81 ans

Compensation Committee Chair

Allan Jacobson

80 ans

Director/Board Member	31/03/1998
Independent Dir/Board Member	31/03/1998

Matthew Klein

54 ans

Director/Board Member

22/03/2023

Anciens Dirigeants et Administrateurs: PTC Therapeutics, Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Alethia Young

Director/Board Member	09/06/2022	08/06/2026
Independent Dir/Board Member	09/06/2022	08/06/2026

Anders Ohberg

Chief Tech/Sci/R&D Officer

01/05/2023

01/02/2025

William Bell

Director/Board Member	05/06/2023	-
Independent Dir/Board Member	05/06/2023	-

Stuart Peltz

Director/Board Member	28/03/2011	22/03/2023
Chief Executive Officer	31/03/1998	22/03/2023
Founder	31/03/1998	22/03/2023

Adrian Haigh

Corporate Officer/Principal

17/09/2014

31/12/2022

Dawn Svoronos

Director/Board Member	13/06/2016	06/12/2022
Independent Dir/Board Member	13/06/2016	06/12/2022

Mark Pykett

Chief Tech/Sci/R&D Officer

01/08/2018

01/01/2021

Edward O'Mara

Corporate Officer/Principal

01/04/2016

01/08/2020

Anne Marie Conway

Corporate Officer/Principal

01/08/2018

01/07/2020

Marcio Souza

Chief Operating Officer	01/05/2017	01/04/2020
Corporate Officer/Principal	01/07/2016	01/05/2017
Sales & Marketing	01/07/2014	01/07/2016

Joseph McIntosh

Corporate Officer/Principal

24/07/2017

01/04/2020

Braden Parker

Corporate Officer/Principal

01/04/2017

01/03/2020

Jodi Cook

Corporate Officer/Principal

01/02/2020

Megan Sniecinski

Corporate Officer/Principal

01/06/2019

Timothy Dyer

Human Resources Officer	01/06/2018	-
Corporate Secretary	-	-

Kylie O'Keefe

Corporate Officer/Principal

01/11/2022

Cameron McDonough

Director/Board Member	06/11/2012	18/09/2017
Independent Dir/Board Member	06/11/2012	18/09/2017

Mark Rothera

Corporate Officer/Principal

23/04/2013

09/08/2017

Adam Koppel

Director/Board Member	01/03/2013	09/06/2017
Independent Dir/Board Member	01/03/2013	09/06/2017

Ronald Renaud

Director/Board Member	10/06/2014	09/06/2017
Independent Dir/Board Member	10/06/2014	09/06/2017

Stephen J. Moloney

Corporate Officer/Principal

01/08/2015

01/05/2017

R. Session

Corporate Officer/Principal

01/10/2013

01/03/2017

Alyssa Wyant

General Counsel

01/03/2015

01/02/2017

Morgan Conn

Corporate Officer/Principal

01/01/2001

01/01/2017

Scott Wilhoit

Corporate Officer/Principal

01/07/2015

01/07/2016

Justine O'Malley

Public Communications Contact

01/07/2016

Robert Spiegel

Chief Tech/Sci/R&D Officer

01/05/2011

26/04/2016

Michael L. Kranda

Director/Board Member	01/12/2003	10/06/2015
Independent Dir/Board Member	01/12/2003	10/06/2015

Richard Aldrich

Director/Board Member	01/03/2013	10/06/2015
Independent Dir/Board Member	01/03/2013	10/06/2015

Cláudia Hirawat

Corporate Officer/Principal	01/09/2000	28/05/2013
President	28/05/2013	-

Axel Bolte

Director/Board Member	01/12/2003	01/07/2014
Independent Dir/Board Member	01/12/2003	01/07/2014

Jay Barth

Chief Tech/Sci/R&D Officer

01/02/2009

02/03/2014

William Hornung

Director of Finance/CFO

01/04/2012

01/03/2014

Tu Yen Ong

Chief Tech/Sci/R&D Officer

01/01/2014

Peter Svennilson

Director/Board Member

01/01/2012

01/01/2014

Emily Hill

Director of Finance/CFO	01/06/2019	-
Investor Relations Contact	01/11/2013	01/06/2019

Martin Rexroad

Human Resources Officer	01/10/2013	-
Corporate Officer/Principal	-	-

Kurt J. W. Andrews

Chief Administrative Officer	01/01/2004	01/07/2013
Human Resources Officer	10/02/2010	01/07/2013

Shane Kovacs

Director of Finance/CFO

03/06/2013

01/05/2017

Søren Knud Carlsen

Director/Board Member

01/08/2001

07/03/2013

Deepa Pakianathan

Director/Board Member

01/01/2009

07/03/2013

Kathryn Haviland

Corporate Officer/Principal

01/03/2007

01/06/2012

Chip Baird

Director of Finance/CFO

01/04/2005

01/04/2012

Manal Morsy

General Counsel

01/06/2007

01/01/2012

Langdon L. Miller

Chief Tech/Sci/R&D Officer

01/07/2003

01/01/2010

William D. Ju

Chief Operating Officer

01/10/2003

01/01/2009

Clare Kennedy

Corporate Officer/Principal

02/06/2009

Theresa Natalicchio

Corporate Officer/Principal	09/10/2009	-
Sales & Marketing	01/07/2007	09/10/2009

Anu Bhattacharyya

Director/Board Member	01/03/2007	-
Corporate Officer/Principal	01/03/2007	-

Carl Goldfischer

Director/Board Member	01/03/2002	-
Independent Dir/Board Member	01/03/2002	-

John Babiak

Corporate Officer/Principal

09/10/2009

Tariq Rana

Founder

31/03/1998

Susanne P. Reilly

Corporate Officer/Principal

Michael S. Cloutier

Corporate Officer/Principal

Brian Spar

Chief Operating Officer	-	-
Human Resources Officer	-	-

Philippe Moyen

Corporate Officer/Principal

John Huynh

Corporate Officer/Principal

Jim Wang

Corporate Officer/Principal

Pius Maliakal

Chief Tech/Sci/R&D Officer

Marc J. Ostro

Director/Board Member

Jane Baj

Public Communications Contact

Serene Forte

Corporate Officer/Principal

Harvey Morrison

Corporate Officer/Principal

Brian N. Cunningham

Corporate Officer/Principal

Josie Yang

Corporate Officer/Principal

Ellen Welch

Chief Tech/Sci/R&D Officer	-	-
Corporate Officer/Principal	-	-

Christopher Trotta

Corporate Officer/Principal

Christopher McNulty

Corporate Officer/Principal

Thomas Davis

Corporate Officer/Principal

Nikolai Naryshkin

Corporate Officer/Principal

David Bradshaw

Corporate Officer/Principal

Jeanne Cunicelli

Director/Board Member

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	15
Femme	9

Dont comité exécutif

Homme	8
Femme	4

Dont Administrateurs

Homme	6
Femme	4

Révisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Non

Controverses sur les droits de l'Homme

Non

Controverses Subventions fiscales

Non

Conforme à la finance Islamique

PTC Therapeutics, Inc. est une société biopharmaceutique d’envergure mondiale. La société se consacre à la découverte, au développement et à la commercialisation de médicaments cliniquement différenciés qui apportent des bénéfices aux enfants et aux adultes atteints de maladies rares. Son portefeuille thérapeutique diversifié comprend plusieurs produits commercialisés et des produits candidats à différents stades de développement, notamment en phases de découverte, de recherche et d’essais cliniques, axés sur la mise au point de nouveaux traitements dans de multiples domaines thérapeutiques liés aux maladies rares touchant la neurologie et le métabolisme. Elle dispose de deux produits, Translarna (ataluren) et Emflaza (deflazacort), destinés au traitement de la dystrophie musculaire de Duchenne (DMD), une maladie rare et potentiellement mortelle. Son produit Upstaza est une thérapie génique destinée au traitement du déficit en L-aminoacide décarboxylase aromatique (AADC), une maladie rare du système nerveux central (SNC). Ses produits Tegsedi et Waylivra sont destinés au traitement de maladies rares. Son produit Evrysdi est un traitement contre l’amyotrophie spinale (SMA).

Employés

Secteur

Produits pharmaceutiques

Agenda

30/07 Publication des résultats - Q2 2026

Plus d'informations sur la société